Semaglutide promoted BMSC proliferation, migration, and osteogenic differentiation through Wnt/LRP5/β-catenin pathway activation, with DKK1 inhibitor reversal and LiCl agonist synergy confirming the mechanism for diabetic osteoporosis treatment.
Wnt bone pathway activatedSemaglutide activated the master bone-forming Wnt/β-catenin pathway in stem cells—potentially making it a dual-purpose drug for diabetes and osteoporosis
What the researchers found
Semaglutide → ↑BMSC proliferation, ↑migration, ↑ALP, ↑mineralization, ↑OCN, ↑RUNX2. RNA-seq → Wnt/LRP5/β-catenin pathway. DKK1 (Wnt inhibitor): partially reversed by semaglutide. LiCl (Wnt agonist) + semaglutide: synergistic osteogenic acceleration.
Why it matters
Diabetic osteoporosis is common and has few treatments that address both diabetes and bone loss. Semaglutide's ability to promote bone formation through Wnt signaling adds a skeletal benefit to its metabolic effects.
How the study worked
In vitro BMSC studies. CCK-8, flow cytometry, ALP/alizarin red staining, wound healing, Western blot, RT-PCR, immunofluorescence, RNA sequencing. DKK1 + LiCl pathway validation.
What this study cannot tell us
In vitro only. BMSCs may respond differently in vivo. Dose translation unclear. Long-term bone effects in humans not studied. Wnt pathway has complex in vivo regulation.
How to read the evidence
In vitro with RNA-seq mechanism discovery and pharmacological validation. Strong mechanism but no in vivo bone data.
When this study was published
Published in 2025.
The bigger picture
The Wnt/β-catenin pathway is the master regulator of bone formation. Finding that semaglutide activates it positions the drug as a potential dual-purpose agent for diabetes and osteoporosis—addressing the "bone-fat balance" disrupted in diabetes.
Questions still open
- Does semaglutide improve BMD in diabetic patients clinically?
- Could combining semaglutide with anti-sclerostin antibodies enhance bone effects?
- Is the bone benefit from direct Wnt activation or secondary to metabolic improvement?
Common questions
Can semaglutide help with osteoporosis?
Why do diabetics get weak bones?
Read the original research
Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway.
Frontiers in pharmacology, 16, 1539411
Citation
Tian, Yawei; Liu, Huiming; Bao, Xiaoxue; Li, Yukun. (2025). Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway.. Frontiers in pharmacology, 16, 1539411. https://doi.org/10.3389/fphar.2025.1539411